home · filing · 0001193125-25-030788
8-K
filed February 20, 2025, 6:59 PM ET
ticker IFF
CIK 0000051253
leadership
confidence high
sentiment neutral
materiality 0.40
IFF: Health & Biosciences president Simon Herriott leaves; Leticia Goncalves Lourenço appointed
INTERNATIONAL FLAVORS & FRAGRANCES INC
Simon Herriott, President of Health & Biosciences, departs IFF on March 31, 2025.
Leticia Goncalves Lourenço appointed as President of Health & Biosciences, effective March 1, 2025.
Herriott's departure qualifies for benefits under IFF's executive severance policy.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2025-03-01
Filed February 20, 2025, 6:59 PM ET
Effective March 1, 2025, Leticia Goncalves Lourenço will join IFF as President of the Company’s Health & Biosciences division.
Effective 2025-03-31
Successor Leticia Goncalves Lourenço
Filed February 20, 2025, 6:59 PM ET
Simon Herriott, who is currently President, Health & Biosciences, will be leaving IFF on March 31, 2025.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Leticia Goncalves Lourenço was appointed as President, Health & Biosciences at INTERNATIONAL FLAVORS & FRAGRANCES INC.
Action will join
Role President, Health & Biosciences
Exact text from the filing
Effective March 1, 2025, Leticia Goncalves Lourenço will join IFF as President of the Company’s Health & Biosciences division.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Simon Herriott departed as President, Health & Biosciences at INTERNATIONAL FLAVORS & FRAGRANCES INC.
Action leaving
Role President, Health & Biosciences
Exact text from the filing
Simon Herriott, who is currently President, Health & Biosciences, will be leaving IFF on March 31, 2025.
View on SEC.gov
Source: SEC EDGAR
accession 0001193125-25-030788
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.